Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 FLT3-ITD confers poor prognosis in patients with acute promyelocytic leukemia treated with AIDA protocols: long-term follow-up analysis.

Literature DB >> 24323990

FLT3-ITD confers poor prognosis in patients with acute promyelocytic leukemia treated with AIDA protocols: long-term follow-up analysis.

Massimo Breccia¹, Giuseppina Loglisci, Maria Giovanna Loglisci, Roberto Ricci, Daniela Diverio, Roberto Latagliata, Robin Foà, Francesco Lo-Coco.
1. breccia@bce.uniroma1.it.

Abstract

Entities: Disease Gene Species

Keywords: FLT3; acute promyelocytic leukemia; internal tandem duplication; poor prognosis

Mesh：

Substances：

Year: 2013 PMID： 24323990 PMCID： PMC3856980 DOI： 10.3324/haematol.2013.095380

Source DB: PubMed Journal: Haematologica ISSN： 0390-6078 Impact factor: 9.941

× No keyword cloud information.

15 in total

1. FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group.

Authors: F M Abu-Duhier; A C Goodeve; G A Wilson; M A Gari; I R Peake; D C Rees; E A Vandenberghe; P R Winship; J T Reilly
Journal: Br J Haematol Date: 2000-10 Impact factor: 6.998

2. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group.

Authors: Francesco Lo-Coco; Giuseppe Avvisati; Marco Vignetti; Massimo Breccia; Eugenio Gallo; Alessandro Rambaldi; Francesca Paoloni; Giuseppe Fioritoni; Felicetto Ferrara; Giorgina Specchia; Giuseppe Cimino; Daniela Diverio; Erika Borlenghi; Giovanni Martinelli; Francesco Di Raimondo; Eros Di Bona; Paola Fazi; Antonio Peta; Alberto Bosi; Angelo M Carella; Francesco Fabbiano; Enrico M Pogliani; Maria C Petti; Sergio Amadori; Franco Mandelli
Journal: Blood Date: 2010-07-19 Impact factor: 22.113

3. Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy.

Authors: Eva Barragán; Pau Montesinos; Mireia Camos; Marcos González; Maria J Calasanz; José Román-Gómez; Maria T Gómez-Casares; Rosa Ayala; Javier López; Óscar Fuster; Dolors Colomer; Carmen Chillón; María J Larrayoz; Pedro Sánchez-Godoy; José González-Campos; Félix Manso; Maria L Amador; Edo Vellenga; Bob Lowenberg; Miguel A Sanz
Journal: Haematologica Date: 2011-06-17 Impact factor: 9.941

4. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials.

Authors: P D Kottaridis; R E Gale; M E Frew; G Harrison; S E Langabeer; A A Belton; H Walker; K Wheatley; D T Bowen; A K Burnett; A H Goldstone; D C Linch
Journal: Blood Date: 2001-09-15 Impact factor: 22.113

5. AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance.

Authors: Giuseppe Avvisati; Francesco Lo-Coco; Francesca Paola Paoloni; Maria Concetta Petti; Daniela Diverio; Marco Vignetti; Roberto Latagliata; Giorgina Specchia; Michele Baccarani; Eros Di Bona; Giuseppe Fioritoni; Filippo Marmont; Alessandro Rambaldi; Francesco Di Raimondo; Maria Grazia Kropp; Giovanni Pizzolo; Enrico M Pogliani; Giuseppe Rossi; Nicola Cantore; Francesco Nobile; Attilio Gabbas; Felicetto Ferrara; Paola Fazi; Sergio Amadori; Franco Mandelli
Journal: Blood Date: 2011-03-08 Impact factor: 22.113

6. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia.

Authors: M Nakao; S Yokota; T Iwai; H Kaneko; S Horiike; K Kashima; Y Sonoda; T Fujimoto; S Misawa
Journal: Leukemia Date: 1996-12 Impact factor: 11.528

7. Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia.

Authors: Rosemary E Gale; Robert Hills; Arnold R Pizzey; Panagiotis D Kottaridis; David Swirsky; Amanda F Gilkes; Elizabeth Nugent; Kenneth I Mills; Keith Wheatley; Ellen Solomon; Alan K Burnett; David C Linch; David Grimwade
Journal: Blood Date: 2005-08-16 Impact factor: 22.113

8. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm.

Authors: Stefan Fröhling; Richard F Schlenk; Jochen Breitruck; Axel Benner; Sylvia Kreitmeier; Karen Tobis; Hartmut Döhner; Konstanze Döhner
Journal: Blood Date: 2002-08-08 Impact factor: 22.113

9. Alterations of the FLT3 gene in acute promyelocytic leukemia: association with diagnostic characteristics and analysis of clinical outcome in patients treated with the Italian AIDA protocol.

Authors: N I Noguera; M Breccia; M Divona; D Diverio; V Costa; S De Santis; G Avvisati; M B Pinazzi; M C Petti; F Mandelli; F Lo Coco
Journal: Leukemia Date: 2002-11 Impact factor: 11.528

10. Treatment outcome of all-trans retinoic acid/anthracycline combination chemotherapy and the prognostic impact of FLT3/ITD mutation in acute promyelocytic leukemia patients.

Authors: Seung-Dok Hong; Yeo-Kyeoung Kim; Hee-Nam Kim; Se Ryeon Lee; Jae-Sook Ahn; Deok-Hwan Yang; Je-Jung Lee; Il-Kwon Lee; Myung-Geun Shin; Hyeoung-Joon Kim
Journal: Korean J Hematol Date: 2011-03-15

14 in total

1. FLT3-ITD impedes retinoic acid, but not arsenic, responses in murine acute promyelocytic leukemias.

Authors: Cécile Esnault; Ramy Rahmé; Kim L Rice; Caroline Berthier; Coline Gaillard; Samuel Quentin; Anne-Lise Maubert; Scott Kogan; Hugues de Thé
Journal: Blood Date: 2019-01-23 Impact factor: 22.113

2. Comparing the epidemiology, clinical characteristics and prognostic factors of acute myeloid leukemia with and without acute promyelocytic leukemia.

Authors: Geetanjali R Kamath; Douglas Tremblay; Alexander Coltoff; Jessica Caro; Guido Lancman; Sheena Bhalla; Vesna Najfeld; John Mascarenhas; Emanuela Taioli
Journal: Carcinogenesis Date: 2019-07-04 Impact factor: 4.944

3. Prevalence and Clinical Significance of FLT3 and NPM1 Mutations in Acute Myeloid Leukaemia Patients of Assam, India.

Authors: Jina Bhattacharyya; Sukanta Nath; Kandarpa Kumar Saikia; Renu Saxena; Sudha Sazawal; Manash Pratim Barman; Dushyant Kumar
Journal: Indian J Hematol Blood Transfus Date: 2017-04-28 Impact factor: 0.900

4. PML-RARα kinetics and impact of FLT3-ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy.

Authors: L Cicconi; M Divona; C Ciardi; T Ottone; A Ferrantini; S Lavorgna; V Alfonso; F Paoloni; A Piciocchi; G Avvisati; F Ferrara; E Di Bona; F Albano; M Breccia; E Cerqui; M Sborgia; M G Kropp; A Santoro; A Levis; S Sica; S Amadori; M T Voso; F Mandelli; F Lo-Coco
Journal: Leukemia Date: 2016-05-02 Impact factor: 11.528

5. Potential Effects of the FLT3-ITD Mutation on Chemotherapy Response and Prognosis of Acute Promyelocytic Leukemia.

Authors: Yu-Hua Song; Peng Peng; Chun Qiao; Jian-Yong Li; Qi-Qiang Long; Hua Lu
Journal: Cancer Manag Res Date: 2021-03-12 Impact factor: 3.989

Review 6. Modeling Myeloid Malignancies Using Zebrafish.

Authors: Kathryn S Potts; Teresa V Bowman
Journal: Front Oncol Date: 2017-12-04 Impact factor: 6.244

7. Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells.

Authors: Jacopo Albanesi; Nelida Ines Noguera; Cristina Banella; Tommaso Colangelo; Elisabetta De Marinis; Stefano Leone; Orazio Palumbo; Maria Teresa Voso; Paolo Ascenzi; Clara Nervi; Fabrizio Bianchi; Alessandra di Masi
Journal: Cells Date: 2020-11-05 Impact factor: 6.600